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Abstract
Background/Aims: Trajectory of heart rate variability (HRV) 
represents a noninvasive real-time measure of autonomous 
nervous system (ANS) and carries the capability of providing 
new insights into the hemodynamic compensation reserve 
during hemodialysis (HD). However, studies on HRV repro-
ducibility during HD are scarce and did not refer to different 
reading periods. In this observational study, we aimed to es-
tablish the best suited and most reliable and reproducible 
HRV index in routine HD treatments including different read-
ing rates. Methods: HRV was characterized by standardized 
mathematical variation expressions of R/R’ intervals: SD of 
all R/R’ intervals (ms), square root of the root mean square of 
the sum of all differences between adjacent R/R’ intervals 
(ms), percentage of consecutive R/R’ intervals that differ by 
> 50 ms (%), low-frequency spectral analysis HRV (LF, ex-
pressing sympathetic activity), and high-frequency HRV (HF, 
expressing parasympathetic activity). To compare robust-
ness of these HRV indices during HD procedures, we com-
pared HRV indices means between different HD sessions and 
controlled for association with clinical parameters. Results: 
In 72 HD treatments of 34 patients, we detected the highest 
reproducibility (89%) of HRV measures when analyzing the 
low-frequency to high-frequency (LF/HF) ratio in long-term 
(3 h) readings. Long-term LF/HF was able to discriminate 
 between patients with and without heart failure NYHA class-
es ≥3 (p = 0.009) and type 2 diabetes (p = 0.023). We were 
unable to study relationships between ANS and intradialytic 
complications because they did not appear in our cohort. 
Short-term readings of HRV indices did not show any sig-
nificance of pattern change during HD. Conclusion: In sum-
mary, our data provide evidence for high robustness of long-
term LF/HF in analyzing HRV in HD patients using future au-
tomated monitoring systems. For short-term analysis, 
mathematical real-time analysis must evolve.
© 2019 S. Karger AG, Basel
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Background
Hemodialysis (HD) is a therapeutical approach associ-
ated with circulatory and pathophysiological changes im-
pacting the patient’s well-being and outcome but at the 
same time providing life-sustaining detoxification and 
fluid removal. To achieve noncomplicated HD proce-
dures, in recent years, attention has been paid to balancing 
relative blood volume (rBV) trajectory and adequate ul-
trafiltration with the ultimate goal to reduce the frequency 
of intradialytic morbid events (IME) [1–7]. In order to 
avoid IME, a sustained cerebral and organ perfusion by 
efficient cardiac output is mandatory. This can be main-
tained as long as sympathetic activity and function of the 
autonomous nervous systems (ANS) ensure effective car-
diac work and vasoconstriction [8, 9]. Few studies demon-
strated the general importance of ANS in this scenario by 
means of “gold standard” microneurography [10] (MSNA) 
during HD [11]. However, this method is invasive and 
does not allow measurements over longer time periods.
Thus, attempts have been made to monitor the func-
tion of ANS by noninvasive and real-time approaches. As 
such, the dynamics of ANS can be assessed by heart rate 
variability (HRV) during HD [12–15]. As a result, it has 
been shown that IME’s may culminate within a phase of 
sudden vagal breakthrough (hypotension, paradoxical 
bradycardia, and vomiting [13]) after sympathetic activ-
ity increased to sustain appropriate peripheral resistance 
[12, 16]. Even though this phenomenon can be controlled 
by volume therapy, it is important to understand that the 
sympathetic (over-) stimulation for maintaining cardiac 
output has a long-term sequelae. In chronic kidney dis-
ease and sympathetic hyperactivity, a specific vascular 
morbidity is created [17, 18]. Insomnia, one of the most 
important components of the complaint burden of dialy-
sis patients [19] is highly significant associated with ANS 
[20]. Hypothetically, it can be assumed that increased 
postdialysis recovery time can be seen as sequelae of 
(hyper)-sympathetic activity. Taking such reasoning to-
gether, a well-tolerated and both acutely and long-term 
event-free dialysis is associated with freedom from IME 
as well as sympathovagal balance. While rBV measure-
ment and regulation during dialysis have been widely in-
vestigated (for review [21]), little is known about result-
ing ANS and the link between intradialytic sympathetic 
activity with long-term morbidity and mortality.
Previous HRV studies in HD patients have shown non-
uniform HRV pattern, with possible impact for subgroups 
of HD patients [8, 13–15, 22, 23]. However, repeated mea-
surements investigating the technical reproducibility of 
different HRV markers have received little attention so 
far. We intended to establish a reliable surrogate of ANS 
which can be used in routine HD treatments and auto-
matically recorded by automated data handling in dialysis 
management systems. We hypothesized that HRV can be 
easily measured with high reproducibility and robustness 
during subsequent HD sessions. The present study was 
designed to gain data of HRV during and after repeated 
HD sessions by different reading rates and to control for 
associations of HRV with patients’ comorbidities.
Material and Methods
HRV Recordings
Electrocardiographic signals (ECG) measured by eMotion 
Faros 180° devices from Mega Electronics Ltd. (Kuopio, Finland) 
were registered during the last 3 h of a dialysis session and the first 
3 h after the end of a session (1,000 Hz) and transferred to a per-
sonal computer. Kubios free HRV software of the Biosignal Analysis 
and Medical Imaging Group (University of Kuopio, Finland) and 
Cardiscope Analytics Software (Gloucestershire, UK) were used for 
preparation and further analysis of standard HRV indices including 
artifact correction (SD of all R/R’ intervals [SDNN, ms], square root 
of the root mean square of the sum of all differences between adja-
cent R/R’ intervals [RMSSD, ms], percentage of consecutive R/R’ 
intervals that differ by > 50 ms [pNN50, %], low-frequency spectral 
analysis HRV [LF], and high-frequency HRV [HF]).
Patient Population, Data Acquisition, and Statistics
This observational study was carried out between June and 
 October 2015 on 34 voluntary maintenance HD patients aged 29–77 
years (23 male, median age 57 years, 6 with diabetes, 8 with NYHA 
[24] classification ≥2, 5 with coronary artery disease [CAD]; Table 
1). Patients confirmed participation agreement by signing informed 
consent sheets (Ethical Committee vote #EK-BR-42/11-1). Repeat-
ed HRV data reading was performed in repeated dialysis sessions 
within the same week excluding long week-end intervals. 
Patients with heart failure NYHA class ≥3 or NYHA class 2 plus 
1 further comorbidity (diabetes or CAD) or NYHA class 1 or 0 plus 
2 other comorbidities were defined having high cardiovascular co-
morbidity profile.
In linear regression analyses and ANOVA, covariates were an-
alyzed by a nonconditional overall model using comorbidity status 
or HRV indices as dependent. Readings of HRV were used for 
ANOVA after logarithmization following non-normal distribu-
tion. Group comparison of categorical values was computed by 
contingency tables and chi-square, whereas numerical values were 
compared by one-factorial ANOVA and independent t test. 
Results
Within the study period of 34 participating pa-
tients  (see description table) and 72 HD sessions, no 



























   
   
   
   
   























by visual analysis, no obvious differences between 
 cardiovascular risk groups of patients were detected 
(Appendix 1–34; doi 10.6084/m9.figshare.9724715). 
Overall distribution of standard long-term HRV pa-
rameters is displayed by boxplots (Fig. 1). While no sig-
nificant pattern changes were notable, the LF/HF ratio 
decreases slightly after dialysis indicating increased 
parasympathetic activity (average of 4 patients Fig. 2), 






















































Fig. 1. Boxplot of HRV parameters 25th–
75th percentile (stars, circles = outliners) 
during and after HD sessions by comorbid-
ity status. HD, hemodialysis; SDNN, SD of 
all R/R’ intervals; RMSSD, square root of the 
root mean square of the sum of all differ-
ences between adjacent R/R’ intervals; 
pNN50, percentage of consecutive R/R’ in-
tervals that differ by > 50 ms; LF/HF, low-
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av. LF/HF (n = 4) over twenty four 5-min-readings
Fig. 2. Average low/high frequency spectral 
HRV analysis readings of 4 patients from 
both cardiovascular groups during twelve 
5-min-readings 3 h before and after HD. LF/
HF, low-frequency/high frequency spectral 
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Analyzing Reproducibility
Paired t tests of long-term HRV indices (3 h) and cor-
relation matrix P-P’ diagrams during different HD peri-
ods and in repeated sessions showed strongest reproduc-
ibility for LF/HF (R = 0.89; R = 0.71) and RMSSD (R = 
0.77; 0.71, Fig. 3).
Long-Term HRV Association with Covariates
Among all investigated HRV indices, LF/HF was as-
sociated with presence of diabetes (p = 0.023) and heart 
failure NYHA classes (p = 0.009). Other clinical and an-
thropometrical parameters (age, gender, time on dialysis, 
CAD, medication [β-blocker]) did not show association 
with any HRV index.
Concerning the association with HD treatment 
 parameters, a multivariate forward regression analysis of 
HRV indices within 3 h HD yielded weak associations (re-
maining parameters in the model) of session time with lg 
RMSSD (B = –0.008 [–0.015 to 0], p = 0.045), lgLF/HF 
(B  = 0.013 [0.03 to 0.24], p = 0.05) and lgpNN50 (B = 
–0.015 [–0.03 to –0.001], p = 0.04), and of serum HBG 
with lgpNN50 (B = –0.39 [–0.74 to –0.49], p = 0.025).
Short-Term Reading of SDNN, LF, HF, and LF/HF 
HRV
To investigate those HRV measures with high repro-
ducibility (SDNN, LF, HF, LF/HF) in shorter readings, 
distinct shorter time intervals (twelve 5 min intervals and 
three 1 h intervals) were computed and displayed before 
and after HD in 4 exemplary patients. Figures 4–6 show 
variability being numerically higher compared to courses 
of R/R’ distances. Because no IME were observed, these 
variations again could not be associated with clinical 
events. No significant pattern change of short-term indi-
ces could be either visualized or computed.
Discussion
Our data provide evidence for high reproducibility 
and robustness of long-term LF/HF methodology in 
analyzing HRV in HD patients using automated moni-
toring systems. Analysis of long-term LF/HF was able 
to discriminate between patients with and without 




































































Fig. 3. Distribution of long-term HRV indices during and after HD 
sessions by comorbidity status. Single data points represent 
 individual patients results during different 3 h HD periods. The 
strongest reproducibility was found for LF/HF after and during 
HD (R = 0.89; R = 0.71) and RMSSD after and during HD (R = 0.77; 
0.71). SDNNs, RMSSD, pNN50, LF/HF. RMSSD, square root of 
the root mean square of the sum of all differences between adjacent 
R/R’ intervals; LF/HF, low-frequency/high frequency spectral 
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SDNN over twenty four 5-min-readings
a b
Fig. 4. Individual courses (n = 4) of SDNN during (a) twelve 5-min-readings and (b) three 1-h-readings 3 h dur-
ing and after HD. Individuals belonging to cardiovascular high comorbidity group are marked by broken lines. 
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LF over twenty four 5-min-readings
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Fig. 5. Individual courses (n = 4) of LF during (a) twelve 5-min-readings and (b) three 1-h-readings 3 h during 
and after HD. Individuals belonging to cardiovascular high comorbidity group are marked by broken lines. LF, 
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HF over twenty four 5-min-readings
Fig. 6. Individual courses (n = 4) of HF during (a) twelve 5-min-readings and (b) three 1-h-readings 3 h during 
and after HD. Individuals belonging to cardiovascular high comorbidity group are marked by broken lines. HF, 
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ces (3 h) were associated with several treatment param-
eters. Of note, there were inverse correlations of session 
time and serum HBG with lg RMSSD and lgpNN50 and 
a direct correlation of session time with lg LF/HF. Al-
though generally speculative, in particular oppositional 
correlations of session time with different HRV indices 
could be seen as an expression of the differing patho-
physiological aspects of HRV markers. 
While the HRV indices with best reproducibility (LF/
HF and SDNN) showed huge short-term variability in 
high-risk patients, we were unable to study relationships 
between HRV and intradialytic complications because 
they did not appear in our cohort. Although a slight ten-
dency to increased parasympathetic activity after dialysis 
was notified by increasing LF/HF, such measures could 
not be statistically approved, because of interindividual 
variability. Such phenomenon indicate a general weak-
ness of our study, which was not able to associate random 
reading rates of every HRV marker of each patient with 
both time course and IME. With the available software 
methods of HRV analysis, a random reading-rate HRV 
analysis is currently not feasible. To evolve the HRV 
method for HD biofeedback, further mathematical inno-
vations in comprehensive datasets including HD param-
eters and real-time clinical events are needed.
The observation that 3-h HRV data in repeated HD ses-
sions were strongly correlated (61–89%) indicates a good 
reliability of the long-term HRV method during and after 
dialysis. These long-term data are in line with another 
long-term HRV study employing repeated measurements 
(14 patients, 8 male [25]). In this study, ECG measure-
ments were taken at 2 dialysis sessions, and reliability was 
measured with excellent interclass correlation > 0.85. 
Numerous studies have been performed to test the reli-
ability of short-term HRV (5 min) in non-HD  populations. 
These studies have shown poor reliability [26–29] pre-
sumably related to higher short-term variability like our 
data. Whether such variability carries a predictive value 
for major clinical events cannot be addressed by our study 
because no IME did occur in our cohort.
Of note, lower reproducibility reported by other au-
thors may depend on multiple factors including comor-
bidities [15, 26, 30]. Related to such reasoning, no intra-
dialytic real-time HRV trajectory is available so far, con-
necting the continuous display of HRV to other real-time 
biosignals as for instance rBV or frequent BP measure-
ments. Such type of interrelated biosignal display could be 
easily implemented in HD systems by cost-effective tech-
nological means. For HRV, only 3 ECG patch electrodes 
and wiring are needed to be integrated in the HD machine. 
Following the results of our study, LF/HF seems to repre-
sent the most suitable ANS parameter for such an ap-
proach. The clinical impact of this real-time technology to 
predict IME and other outcomes needs to be studied in 
Table 1. Clinical, anthropometrical and dialysis data by comorbidity status
Parameter Comorbidity status groups p value
standard (n = 24) high (n = 10) all (n = 34)
Age, years, mean ± SD 52±14 64.6±11.6 55.7±14.4 0.017
Time on HD (vintage years), mean ± SD 7.0±7.0 4.7±3.8 6.3±6.2 0.35
Gender, female, n (%) 9 (38) 2 (20) 11 (32) 0.28
Diabetes, n (%) 2 (8) 4 (40) 6 (18) 0.048
CAD, n (%) 3 (12.5) 2 (20) 5 (14) 0.46
NYHA ≥3, n (%) 0 (0) 8 (80) 8 (23.5) <0.0001
Full-dose β-block, n (%) 2 (12) 3 (20) 5 (15) 0.47
Non-full β-block, n (%) 14 (58) 7 (70) 21 (62) 0.47
HD session time, mean ± SD 256±14.4 254±13.9 255±14.1 0.72
UF, L, mean ± SD 1.84±1.20 2.12±0.958 1.92±1.08 0.50
Ideal weight, kg, mean ± SD 74.5±17.0 79.7±12.0 76.0±15.7 0.39
Inter HD weight gain, kg, mean ± SD 1.5±1.1 1.8±1.2 1.6±1.1 0.51
Kt/V, mean ± SD 1.5±0.2 1.5±0.3 1.5±0.3 0.78
Phosphorus, mmol/L, mean ± SD 2.0±0.5 1.5±0.4 1.8±0.5 0.01
HBG, mmol/L, mean ± SD 6.6±0.6 6.3±0.6 6.5±0.6 0.28
ESA/week, IU, mean ± SD 8,697±5115 6,788±5168 8,136±5128 0.33
BP pre, mm Hg, mean ± SD 142.7/84.6±22.2/12.6 142.8/73.9±24.1/11.1 142.7/81.4±22.4/12.9 0.99/0.03
BP after, mm Hg, mean ± SD 138.5/78.0±28.8/12.6 138.1/73.6±28.1/9.8 138.4/76.7±28.2/11.9 0.97/0.33
Heart rate pre, 1/min, mean ± SD 78.6±12.8 74.1±13.1 77.4±12.8 0.38
Heart rate after, 1/min, mean ± SD 71.2±9.2 72.7±11.4 74.4±11.6 0.63



























   
   
   
   
   























future trials. The large-scale development and validation 
of structured and interrelated HD patient’s biodata may 
guide HD process by personalized decision support tools.
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